RNA Interference-based Therapies for the Reduction of Cardiovascular Risk

Title:RNA Interference-based Therapies for the Reduction of Cardiovascular Risk

Volume: 17

Author(s): Natalia Nazarenko, Jiyoung Seo, Sanjana Nagraj, Leonidas Palaiodimos and Damianos G. Kokkinidis*

Affiliation:

• Section of Cardiovascular Medicine, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06510, USA

Keywords: RNA interference, ASO, siRNA, Cardiovascular risk reduction, Lipid lowering therapy, LDL, Lp(a).

Abstract: Globally, there remains an unwavering increase in the incidence of cvd - from 271 million in 1990 to 523 million in 2019. Among the several modifiable and non-modifiable risk factors of heart disease, dyslipidemia is an important and prevalent risk factor mediated by both genetics and lifestyle factors. Hence, lowering lipid levels, specifically, ldl-c levels (low-density lipoprotein cholesterol), is a key strategy in decreasing the risk of cardiovascular disease. A reduction of 20 mg/dl in ldl-c levels has been found to prevent 2-3 cases of coronary artery disease (cad) for every 1000 individuals. Studies have also found reductions in ldl-c levels to be associated with a mortality benefit. However, ldl-c levels reduction may not eliminate the risk of significant cardiovascular events.

Cite this article as:

Nazarenko Natalia, Seo Jiyoung, Nagraj Sanjana, Palaiodimos Leonidas and Kokkinidis G. Damianos*, RNA Interference-based Therapies for the Reduction of Cardiovascular Risk, Current Molecular Pharmacology 2024; 17 : e18761429264553 . https://dx.doi.org/10.2174/0118761429264553231204115314